Wegovy for Teens: A Pediatric Specialist's Guide to GLP-1 Medication for Adolescents

Wegovy for teens (semaglutide 2.4 mg) is an FDA-approved GLP-1 medication for adolescents age 12 and older with obesity. It is one tool inside a pediatric stepped-care treatment plan, not a standalone weight-loss drug. The STEP TEENS trial in The New England Journal of Medicine showed meaningful BMI reduction when semaglutide was paired with behavioral lifestyle support and prescribed by a pediatric specialist.

What Wegovy is, and how it works in adolescents

Wegovy is the brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone the gut releases after eating. It tells the brain you are full, slows how fast the stomach empties, and improves how the body manages blood sugar. Semaglutide is a longer-acting version of that natural signal.

In adolescents, Wegovy works on the same biology that defends a person's weight set-point. It does not "burn fat" or speed up metabolism. It quiets appetite and food preoccupation so that nutritional and behavioral changes can stick. Pediatric specialists do not describe Wegovy as a diet drug, because it is not. It is medical treatment for a chronic condition.

The FDA expanded the Wegovy indication to adolescents 12 and older on December 23, 2022, when their BMI is at or above the 95th percentile for age and sex. It is given as a once-weekly subcutaneous injection, started at a low dose and increased gradually over several months under specialist supervision. The right maintenance level is individualized to each teen based on tolerance and response, so it is not a single fixed dose. The FDA-approved prescribing information on DailyMed is the authoritative source for the label and contraindications.

What the STEP TEENS trial actually showed

The STEP TEENS trial is the pivotal study that supported FDA approval of Wegovy for adolescents. Published in The New England Journal of Medicine in late 2022 by Weghuber and colleagues, it enrolled 201 adolescents ages 12 to under 18 with obesity. They were randomized 2:1 to semaglutide 2.4 mg once weekly or placebo. Both arms received behavioral lifestyle counseling delivered to teens and a parent or guardian. Active treatment ran 68 weeks.

Key results:

• Mean BMI change at week 68 was a 16.1% reduction with semaglutide vs. a 0.6% increase with placebo (a 16.7 percentage-point difference, P < 0.001).
• 73% of adolescents on semaglutide lost at least 5% of their body weight, compared with 18% on placebo.
• Waist circumference, triglycerides, and HbA1c improved more on semaglutide than on placebo.
• A validated quality-of-life measure (IWQOL-Kids) showed statistically significant improvement on semaglutide vs. placebo.

What does a 16.1% BMI reduction mean for a teen at the 99th percentile? In lived terms, it is the difference between continuing a steep upward weight trajectory and bending that trajectory back toward where the teen's growth chart would predict. It does not mean every teen on Wegovy will achieve that average, and it does not erase the underlying biology of obesity.

The trial has honest limits. The active period was 68 weeks. The study population was 62% female and 79% white, so generalizability to Black and Hispanic adolescents is limited. The trial was sponsored by the manufacturer, Novo Nordisk. Long-term durability beyond 68 weeks and discontinuation-and-regain dynamics in adolescents specifically are still being studied. For a parent-language walkthrough of these numbers, see our STEP TEENS trial explained for parents.

How Wegovy fits the AAP 2023 stepped-care framework

In 2023, the American Academy of Pediatrics published its Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. The guideline is the current consensus on how pediatric obesity should be treated. It organizes care into stepped layers: nutrition and behavior counseling, intensive health behavior and lifestyle treatment (IHBLT), pharmacotherapy, and metabolic and bariatric surgery for adolescents who meet criteria.

For adolescents 12 and older with obesity, the AAP recommends that clinicians "offer weight-loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment." The single most important word in that sentence is adjunct. Pharmacotherapy is added on top of intensive lifestyle treatment, not in place of it.

In practice, medication is not a shortcut around behavior, nutrition, sleep, movement, and family support. Those layers stay active, get more effective when paired with a medication that lowers the biological resistance to change, and are what makes any later step-down sustainable.

Your pediatric clinician will assess eligibility. Medication is one option in a treatment plan, not a default. For more on stepped care and how Blueberry Balance organizes the layers, see our guide on pediatric weight management.

Is Wegovy safe for teens?

The pediatric-specific safety profile of Wegovy comes from the 68-week STEP TEENS trial and the FDA-approved label. The safety profile is more reassuring than most online chatter suggests, though a few caveats deserve a real conversation with a pediatric specialist.

Most common side effects (from STEP TEENS):

• Nausea: 42% on semaglutide vs. 18% on placebo
• Vomiting: 36% vs. 10%
• Diarrhea: roughly 22% vs. 19%
• Abdominal pain and headache also occurred at higher rates than placebo

Most gastrointestinal events were mild to moderate, clustered during the 16-week dose escalation, and resolved without stopping treatment. Only 5% of adolescents in the trial discontinued semaglutide because of side effects. In practice, pediatric obesity specialists often extend the titration further than the trial protocol if a teen has poor GI tolerance. Slowing the climb makes a meaningful difference.

Serious but less common considerations:

• Boxed warning, thyroid C-cell tumors. Semaglutide caused thyroid C-cell tumors in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). A pediatric specialist will screen the family history before prescribing.
• Gallbladder events. Cholelithiasis (gallstones) was reported in 4% of adolescents on semaglutide and 0% on placebo in STEP TEENS. The signal is small but real, and it deserves to be named rather than buried.
• Pancreatitis. Zero cases were reported in STEP TEENS, but the AAP CPG already lists pancreatitis history as a relative contraindication, and pediatric specialists monitor for it.
• Mental-health monitoring. A 2024 JAMA Pediatrics analysis by Kerem and Stokar found teens on a GLP-1 receptor agonist had a 33% lower 12-month risk of suicidal ideation or attempt than teens on lifestyle-only care. The study compared 6,912 propensity-matched adolescent pairs, so the findings are observational, not from a randomized trial. The FDA removed the suicidal-ideation class warning from semaglutide labeling in January 2026. Pediatric specialists still screen for mood and behavioral changes routinely, per AAP guidance.
• Eating-disorder screening. The AAP recommends formal eating-disorder screening alongside obesity treatment. An active restrictive eating disorder is a contraindication to GLP-1 prescribing in adolescents.

Growth, puberty, and bone density are covered more deeply in our guide on Wegovy and adolescent puberty, growth, and bone density. STEP TEENS did not report differences in growth velocity, Tanner stage, or bone density between arms, though those were not primary endpoints. Research on adolescent bone metabolism during long-term GLP-1 therapy is active, including a two-year prospective study now enrolling.

For more, see our complete guide to Wegovy side effects in teens and our pediatric safety deep dive.

If you are considering Wegovy for your teen, the right next step is a conversation with a pediatric obesity medicine specialist. Talk to a pediatric obesity medicine specialist first.

How long will my teen need to take Wegovy?

This is the question parents ask most often in our intake visits, and it deserves an honest answer rather than a comforting one.

Pediatric obesity is a chronic condition, and like other chronic conditions, treatment is typically ongoing rather than a short course. The adult evidence on stopping semaglutide is sobering: in adults who discontinued after a year of treatment, most of the weight loss was regained within twelve months. Adolescent-specific long-term discontinuation data are not yet published. The longest adolescent post-discontinuation observation in STEP TEENS was 7 weeks, and even in that short window mean BMI began rising from a 16.1% reduction back toward 13.2% reduction.

GLP-1 medications quiet the body's hormonal hunger signals while the drug is on board. When the medication stops, those signals return, food intake rises, and weight regain follows the same biology that defends weight at baseline.

In our practice, the conversation about how long your teen will be on medication starts at the first visit. We plan dose maintenance and any step-down, monitor weight trajectory after any change, keep behavioral support active throughout, and define in advance the criteria for re-initiation if weight regain returns. Stopping is a clinical decision, not a milestone.

For a deeper look at our stepped-care and maintenance approach, see our guide on Wegovy stepped care and off-ramp planning.

Wegovy vs. other GLP-1 medications for teens

Two GLP-1 receptor agonists are currently FDA-approved for adolescents 12 and older with obesity: Wegovy (semaglutide), given weekly, and Saxenda (liraglutide), given daily. Both target the same hormonal pathway.

Zepbound (tirzepatide) is FDA-approved for adults but is not approved for adolescents as of May 2026. A phase 3 adolescent tirzepatide trial has finished enrolling but has not yet reported results. Until the FDA reviews adolescent data, Blueberry Balance prescribes within the FDA's adolescent indications.

A note on compounded GLP-1s. Blueberry Balance does not prescribe compounded GLP-1 products for adolescents. Compounded semaglutide is not FDA-approved, has no pediatric safety data, and has been the subject of repeated FDA safety communications.

For a fuller comparison, see our guide on Wegovy vs. Zepbound for teens.

Pediatric specialist care vs. adult telehealth retrofitted for teens

If you have searched for GLP-1 telehealth or GLP-1 for teens, you have probably been quoted by an adult clinic. The volume of adult Wegovy and Zepbound prescribing online is large, and most platforms have not built around adolescent care.

A pediatric obesity medicine specialist looks at the whole adolescent: growth velocity, pubertal stage, family medical history, comorbidities, mental-health context, eating-pattern history, sleep, and the family system the teen lives inside. They titrate dose differently when GI tolerance is poor, screen for eating-disorder risk on the schedule the AAP recommends, and plan monitoring and stepped-care escalation or de-escalation with the teen in the room. That is the work an adult platform does not typically do, because their patients are adults.

Cost, coverage, and access for adolescent Wegovy

Cost is the question most likely to delay care. Three layers to know:

Insurance coverage is highly variable. Many employer-sponsored commercial plans still exclude anti-obesity medications categorically, a holdover from when these medications were classified as lifestyle drugs. For plans that do cover adolescent Wegovy, approval usually requires BMI at or above the 95th percentile and at least one weight-related comorbidity, even though the FDA indication only requires the BMI criterion. Medicaid coverage is heterogeneous state by state.

Prior authorization is the norm. Common criteria include BMI documentation, evidence of a prior lifestyle-intervention attempt, comorbidity presence, and prescriber specialty (some plans restrict to endocrinology or obesity-medicine specialists). PA decisions commonly take two to six weeks, and renewals every six to twelve months may require documented response to maintain coverage. For the workflow, see our prior authorization parent guide.

Manufacturer savings card. The Wegovy Savings Offer requires commercial (private) prescription insurance, excludes patients enrolled in Medicare, Medicaid, VA, DOD, or TRICARE, and is administered by Novo Nordisk on terms that change periodically. Families should verify current adolescent eligibility directly with NovoCare before assuming a copay reduction is available; several secondary sources report an 18-and-older requirement, though the manufacturer's published eligibility terms do not explicitly state an age minimum.

How to talk to your teen about starting Wegovy

How a parent introduces medication shapes how a teen receives it. Three principles pediatric obesity specialists recommend:

• Lead with biology, not willpower. Obesity is a chronic condition, not a character flaw, and medication treats biology.
• Frame medication as treatment, not punishment. The goal is health and quality of life, not appearance.
• Include the teen in the decision. A teen who feels consulted stays more engaged in the full treatment plan.

How Blueberry Balance works for families considering Wegovy

Blueberry Balance is a telehealth pediatric obesity medicine practice led by Dr. Makia Powers (DABOM). Intake includes medical history, comorbidity screen, family context, mental-health screen, and a review of weight trajectory on the growth chart. A GLP-1 conversation is one possible outcome of intake, not a default.

If medication is appropriate, ongoing care includes dose titration tuned to GI tolerance, side-effect monitoring, behavioral support for the teen and family, planned maintenance, and defined criteria for step-down and re-initiation. For families whose teen is not a medication candidate, or who prefer a lifestyle-only path, see our lifestyle-only program.

The single most common question I hear from parents in a Wegovy intake is not about side effects or whether it works. It is some version of, "Will my child be on this forever?" The most useful answer starts with how we plan the dose and the follow-up from day one, not whether stopping is on the table. Pediatric obesity is a chronic condition, and we treat it that way. We monitor the response, we adjust the dose to the lowest effective level for maintenance, we keep behavioral support active throughout, and we define in advance the criteria for any planned step-down and for re-initiation if weight regain returns. The off-ramp is not a finish line. It is a planned part of the protocol.

Dr. Makia Powers, MD, DABOM

Frequently asked questions

At what age can a teen start Wegovy?

Wegovy is FDA-approved for adolescents 12 and older whose BMI is at or above the 95th percentile for age and sex. A pediatric specialist will assess whether medication is appropriate for your teen specifically.

Will my teen need to be on Wegovy forever?

Pediatric obesity is chronic, and treatment is typically ongoing rather than a short course. In adult studies of semaglutide withdrawal, most weight loss was regained within a year of stopping; adolescent-specific long-term data are not yet published. In our practice, dose maintenance and step-down criteria are planned from the first visit.

What if my teen wants to stop?

Stopping happens with the teen, the family, and the pediatric specialist together. We monitor the response, plan any step-down deliberately, and re-initiate if weight regain returns and clinical criteria are met.

How much weight will my teen lose?

In STEP TEENS, the average BMI reduction at 68 weeks was 16.1% on semaglutide vs. a 0.6% increase on placebo, both groups receiving behavioral lifestyle support. Individual response varies. The right frame is BMI trajectory and metabolic health, not a guaranteed number.

Will Wegovy affect my teen's growth or puberty?

STEP TEENS did not report differences in growth velocity, Tanner stage, or bone density between arms, though those were not primary endpoints. Pediatric specialists monitor growth and pubertal development throughout treatment. See our puberty, growth, and bone density guide.

Does my insurance cover Wegovy for teens?

Coverage varies. Many commercial plans exclude anti-obesity medications, and those that cover Wegovy typically require prior authorization with BMI documentation and a comorbidity. See our prior authorization parent guide.

Is Wegovy a "diet drug"?

No. Wegovy is a GLP-1 receptor agonist that targets the hormonal biology of appetite regulation. It is medical treatment for a chronic condition, prescribed and monitored by a clinician.

What if Wegovy does not work for my teen?

Response varies. If a teen does not respond, the pediatric specialist reassesses dose, adherence, behavioral co-treatment, and whether another stepped-care option (a different medication, or in selected cases, metabolic and bariatric surgery for adolescents who meet criteria) is appropriate.

Medical disclaimer: This article is for informational purposes and is not a substitute for medical advice from a licensed pediatric clinician who knows your child. Talk to a pediatric specialist about your teen's specific situation before starting, changing, or stopping any medication.

References

• Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245-2257.
• Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023;151(2):e2022060640.
• US Food and Drug Administration. Wegovy (semaglutide injection, solution) prescribing information, DailyMed.
• Kerem L, Stokar J. Risk of suicidal ideation or attempts in adolescents with obesity treated with GLP-1 receptor agonists. JAMA Pediatr. 2024;178(12):1307-1315.
• Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022.
• Bensignor MO, Arslanian S, Vajravelu ME. Semaglutide for Management of Obesity in Adolescents: Efficacy, Safety, and Considerations for Clinical Practice. Curr Opin Pediatr. 2024;36(4):449-455.